JSL
NBSE

JT Stratford LLC’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

JT Stratford LLC’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25
Closed -$19K – 117
2017
Q4 		$19K Hold
25
– – 0.01% 102
2017
Q3 		$7K Hold
25
– – ﹤0.01% 107
2017
Q2 		$6K Hold
25
– – ﹤0.01% 105
2017
Q1 		$8K Buy
+25
New +$11.6K 0.01% 105

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

JT Stratford LLC's NBSE Position: Q1 2018 in Review

JT Stratford LLC sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 25 shares — an estimated $19K sold.

JT Stratford LLC first reported a position in NBSE in Q1 2017 and held it in 4 quarters. The position peaked at $19K in Q4 2017. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

  • JT Stratford LLC reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • JT Stratford LLC sold 25 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $19K.
  • JT Stratford LLC first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • JT Stratford LLC's NeuBase Therapeutics, Inc. Common Stock position peaked at $19K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on JT Stratford LLC's 13F filing for Q1 2018, filed 14 May 2018.